BACKGROUND: Risk stratification is a major challenge in bladder cancer (BC), and a biomarker is needed. Multiple studies have reported the neutrophil-to-lymphocyte ratio (NLR) as a promising candidate; however, these analyses have methodological limitations. Therefore, the authors performed a category B biomarker study to test whether NLR is prognostic for overall survival (OS) after curative treatment or is predictive for the survival benefit from neoadjuvant chemotherapy (NAC). METHODS: This study is an unplanned secondary analysis of SWOG 8710, a randomized phase 3 trial that assessed cystectomy with or without NAC in 317 patients with muscle-invasive BC. NLR was calculated from prospectively collected complete blood counts. For the prognostic analysis, 230 patients were identified; for the predictive analysis, 263 were identified. NLR was evaluated with proportional hazards models including prespecified factors (age, sex, T-stage, lymphovascular invasion, and treatment arm). RESULTS: With a median follow-up of 18.6 years, there were 172 and 205 deaths in the prognostic and predictive cohorts, respectively. In a multivariable analysis, NLR was not prognostic for OS (hazard ratio [HR], 1.04; 95% confidence interval [CI], 0.98-1.11; P = .24). Furthermore, NLR did not predict for the OS benefit from NAC (HR, 1.01; 95% CI, 0.90-1.14; P = .86). Factors associated with worse OS were older age (HR, 1.05; 95% CI, 1.04-1.07; P < .001) and surgery without NAC (HR, 1.39; 95% CI, 1.03-1.88; P = .03). CONCLUSIONS: This is the first analysis of NLR in BC to use prospectively collected clinical trial data. In contrast to previous studies, it suggests that NLR is neither a prognostic nor predictive biomarker for OS in muscle-invasive BC. Cancer 2017;123:794-801.
RCT Entities:
BACKGROUND: Risk stratification is a major challenge in bladder cancer (BC), and a biomarker is needed. Multiple studies have reported the neutrophil-to-lymphocyte ratio (NLR) as a promising candidate; however, these analyses have methodological limitations. Therefore, the authors performed a category B biomarker study to test whether NLR is prognostic for overall survival (OS) after curative treatment or is predictive for the survival benefit from neoadjuvant chemotherapy (NAC). METHODS: This study is an unplanned secondary analysis of SWOG 8710, a randomized phase 3 trial that assessed cystectomy with or without NAC in 317 patients with muscle-invasive BC. NLR was calculated from prospectively collected complete blood counts. For the prognostic analysis, 230 patients were identified; for the predictive analysis, 263 were identified. NLR was evaluated with proportional hazards models including prespecified factors (age, sex, T-stage, lymphovascular invasion, and treatment arm). RESULTS: With a median follow-up of 18.6 years, there were 172 and 205 deaths in the prognostic and predictive cohorts, respectively. In a multivariable analysis, NLR was not prognostic for OS (hazard ratio [HR], 1.04; 95% confidence interval [CI], 0.98-1.11; P = .24). Furthermore, NLR did not predict for the OS benefit from NAC (HR, 1.01; 95% CI, 0.90-1.14; P = .86). Factors associated with worse OS were older age (HR, 1.05; 95% CI, 1.04-1.07; P < .001) and surgery without NAC (HR, 1.39; 95% CI, 1.03-1.88; P = .03). CONCLUSIONS: This is the first analysis of NLR in BC to use prospectively collected clinical trial data. In contrast to previous studies, it suggests that NLR is neither a prognostic nor predictive biomarker for OS in muscle-invasive BC. Cancer 2017;123:794-801.
Authors: Matthew J Resnick; Meredith Bergey; Laurie Magerfleisch; John E Tomaszewski; S Bruce Malkowicz; Thomas J Guzzo Journal: BJU Int Date: 2010-09-29 Impact factor: 5.588
Authors: Michael J Barry; Gerald L Andriole; Daniel J Culkin; Steven H Fox; Karen M Jones; Maureen H Carlyle; Timothy J Wilt Journal: Clin Trials Date: 2013-08-29 Impact factor: 2.486
Authors: Aaron Potretzke; Luke Hillman; Kelvin Wong; Fangfang Shi; Ryan Brower; Stephanie Mai; Jeremy P Cetnar; Edwin Jason Abel; Tracy M Downs Journal: Urol Oncol Date: 2014-03-12 Impact factor: 3.498
Authors: Belinda Yeo; Andrew D Redfern; Kellie A Mouchemore; John A Hamilton; Robin L Anderson Journal: Clin Exp Metastasis Date: 2018-07-02 Impact factor: 5.150
Authors: Matteo Ferro; Giuseppe Di Lorenzo; Carlo Buonerba; Giuseppe Lucarelli; Giorgio Ivan Russo; Francesco Cantiello; Abdal Rahman Abu Farhan; Savino Di Stasi; Gennaro Musi; Rodolfo Hurle; Serretta Vincenzo; Gian Maria Busetto; Ettore De Berardinis; Sisto Perdonà; Marco Borghesi; Riccardo Schiavina; Gilberto L Almeida; Pierluigi Bove; Estevao Lima; Giovanni Grimaldi; Deliu Victor Matei; Francesco Alessandro Mistretta; Nicolae Crisan; Daniela Terracciano; Verze Paolo; Michele Battaglia; Giorgio Guazzoni; Riccardo Autorino; Giuseppe Morgia; Rocco Damiano; Matteo Muto; Roberto La Rocca; Vincenzo Mirone; Ottavio de Cobelli; Mihai Dorin Vartolomei Journal: J Cancer Date: 2018-10-20 Impact factor: 4.207